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Editorial 
Assessing equivalence of inhaled drugs 
The move to disease management has led to an increase in the practice of drug or formulation substitution on 
the basis of equivalence. Well established guidelines are available for judging equivalence between oral, but 
not inhaled, formulations. This article describes the criteria by which equivalence can be assessed and 
concludes that although traditional issues such as adequate sample size are important, studies also need to be 
designed in such a way as to avoid the possibility of falsely concluding clinical equivalence. 
Introduction 
The new trend towards disease management raises 
important issues as there are increasing demands to 
reduce the number of drugs/formulations stored 
within a pharmacy, and in some countries substi- 
tutions between formulations is taking place. For the 
treatment of obstructive airway disease, although the 
number of different classes of inhaled drugs remains 
small, there is an increasing number of drugs within 
each class. In addition, any one drug may have 
different types of formulation, i.e. powder or metered 
dose inhaler (MDI), and may even have a number of 
formulations within each of those types on the 
market. In a recurrent Workshop (l), general points 
on equivalence testing of inhalers was discussed. This 
article will discuss the criteria by which different 
drugs for formulations should be compared to deter- 
mine their equivalence, which would enable rational 
pharmacy stocking and substitution. 
Usually a new drug in a therapeutic class has its 
safety and efficacy profile fully established within the 
registration process. However, approval for a change 
in formulation may be based on much less data, even 
data limited to pharmaceutical rather than clinical 
performance. It is therefore in the latter case where 
careful assessment of the data is required. 
Clear differences between drugs or formulations 
can be established relatively easily by statistical 
studies to reject the Null hypothesis. However, the 
presence of true equivalence is not so readily proven, 
as poor study design or interpretation can result in 
the perception of equivalence which is in fact not the 
case. Apparent equivalence can lead to the use of 
drugs with reduced efficacy or increased risk, both of 
which would be unacceptable when safe and effective 
drugs and formulations are already available. The 
problems of such apparent equivalence were high- 
lighted at a Food and Drug Administration (FDA) 
advisory meeting on generic drugs in the U.S.A. At 
0954-6111/95/080525+03 $12.0010 
that meeting, Cuss showed data comparing a salbuta- 
mol MD1 and powder formulation which had iden- 
tical efficacy, but the powder formulation gave 
increased systemic side-effects. Such a difference 
between formulations has been shown in another 
study comparing salbutamol powder to terbutaline 
powder, where a similar efficacy but a different safety 
profile was observed (2). These cases did not show 
apparent equivalence but they do raise the need for 
close scrutiny of the available data. 
History of Equivalence Testing 
Two decades ago it was common practice to 
demonstrate bioequivalence of drug formulations by 
comparing blood levels in only a few volunteers 
(often six or less), with the consequence that only 
massive differences in formulations could be detected 
statistically. The low statistical power inevitably 
resulted in a complete lack of any statistical differ- 
ence which was often misinterpreted as strong 
evidence that the two formulations were equivalent. 
Thus lack of evidence for showing a difference was 
taken as evidence of no difference between the drugs, 
rather than concluding that the very limited data did 
not support any conclusion. This led to gradual 
demands for bigger studies which caused the opposite 
effect, i.e. rejection of reasonable pharmaceutical 
bioequivalence because of statistical detection of 
trivially small differences. The more one tried to 
demonstrate bioequivalence by using large sample 
sizes, the more likely it became that bioequivalence 
would be rejected. This paradox was finally resolved 
by Schuirmann who in 1987 (3) proposed a new 
confidence interval approach which was subsequently 
adopted as the FDA Guidelines in 1992 (4). The 
principle behind this is to first define the maximum 
difference that is acceptable between formulations for 
them to still be accepted as clinically equivalent. The 
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Fig. 1 The potential pitfalls of equivalence studies. (a) Potential false equality. Two formulations were studied in patients 
with mild, moderate and severe asthma. In mild and severe asthma they are apparently equivalent. However, in moderate 
asthma there is a clear difference between formulations. (b) True equality. This shows how the data should look in a true 
equivalence study. The results of the two formulations show equivalence, both formulations are clearly more effective than 
placebo and less effective than maximum. W, 0, severe asthma; A, A, moderate asthma; 0, 0, mild asthma. 
statistical test hypothesis is then re-arranged so that 
the confidence intervals of the differences have to 
fall within set limits (usually f 20%). This principle 
has the effect that increased sample size results in 
a greater chance of statistically rejecting ‘non- 
equivalence’ of two equivalent formulations. This 
statistical approach is appropriate for determining 
bioequivalence as measured by pharmacokinetic 
parameters of drug blood levels. However, when 
applied to clinical efficacy parameters, there are 
additional factors which can give rise to a misleading 
or an apparent conclusion. 
Single Dose Clinical Studies 
The pharmacokinetic approach can be applied 
to single dose studies measuring lung function 
parameters, e.g. assessing peak effect of broncho- 
dilators. There can be little doubt that a study which 
demonstrates identical dose-response over the same 
dose range of the same or similar drugs with 
adequate sample size gives acceptable information to 
claim equivalence (5). The same would be true for 
relative safety if systemic effects were measured, 
for example, with a P-agonist (6). However, even 
cumulative dose-response data can be misleading if 
the dose range is different or the duration of action of 
the drugs is not equal, as with such a design the 
influence of the earlier dosing will alter the response 
to subsequent doses. 
It is also possible to design single dose studies to 
compare the duration of action of inhaled drug if the 
following criteria are included. First, the data 
must achieve the criteria for equivalence vis-ri-vis the 
pharmacokinetic study. In addition, the response 
must be statistically less than the maximum achieved 
in the patients’ group by a reference drug (short 
acting &agonist) and greater than placebo or 
baseline. (Fig. 1). Similar design can be applied to 
bronchial challenge which can be a useful parameter 
for measuring both bronchodilators and drugs such 
as sodium cromoglycate. There is, however, no single 
dose study appropriate for comparing glucocortico- 
steroids, as single dose pharmacokinetic studies 
with corticosteroids only give information about 
safety and no efficacy interpretation can be made. 
Therefore, a multiple dose approach is required. 
Multiple Dose Clinical Studies 
Multiple dose studies have similar pitfalls to single 
dose studies. The primary efficacy variable must fulfil 
the criteria for equivalence. However, as with single 
dose studies, there are two outcomes where data 
providing adequate statistical equivalence may in fact 
be demonstrating misleading clinical equivalence. 
These are when both treatments have no effect (7) 
or when both treatments have had the maximum 
possible effect in the patients (8). To ensure that this 
will not happen, all multiple dose studies should 
incorporate a determination of the maximum 
possible shift in a primary efficacy variable. This 
could be achieved by giving a standard dose of a 
bronchodilator. If possible, all studies should contain 
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a placebo limb. Then, the data must show that both References 
treatments have significantly more effect than 
placebo and that the effect is below the maximum 
value before true equivalence can be inferred (Fig. 1). 
If placebo limbs are not ethically possible, it may be 
acceptable to compare study data with a prolonged 
stable run-in to make the judgement that both drugs 
have had an effect. 
Conclusion 
The demonstration of equivalence between inhaled 
drugs requires special consideration as the pharma- 
cokinetic approach used for oral drugs is relevant for 
side-effects, not efficacy of topical formulations. 
However, the same statistical principle that deter- 
mines the equivalence can be used if the study design 
is adequate in addressing the following points. 
First, will the sample size be adequate to have 
ensured that the study had enough statistical power 
to detect non-equality if it was present? Second, will 
any evidence be obtained to show that the treatments 
were better than placebo or at least baseline? Third, 
will the responses be below the maximum possible 
clinical change? 
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